CURRENT APPROACHES TO DIAGNOSING PROSTATE CANCER, BY APPLYING MAGNETIC RESONANCE SPECTROSCOPY (A CLINICAL STUDY)

<p<By evaluating abnormal metabolism, magnetic resonance spectroscopy (MRS) is a highly effective tool for diagnosing prostate cancer (PC). Our study has indicated that the level of citrate (Ci) and the ratio of the content of choline (Cho) and creatine (Cr) to that of citrate ((Cho + Cr)/Ci)...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	E. A. Moskalenko [verfasserIn] S. B. Petrov [verfasserIn] Yu. V. Tolkach [verfasserIn] A. V. Mishchenko [verfasserIn]

Format:	E-Artikel
Sprache:	Russisch

Erschienen:	2014

Schlagwörter:	prostate cancer magnetic resonance spectroscopy citrate choline creatine

Übergeordnetes Werk:	In: Onkourologiâ - ABV-press, 2015, 7(2014), 1, Seite 25-30
Übergeordnetes Werk:	volume:7 ; year:2014 ; number:1 ; pages:25-30

Links:	Link aufrufen Link aufrufen Journal toc Journal toc

Katalog-ID:	DOAJ065623843

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ065623843
003	DE-627
005	20230228043827.0
007	cr uuu---uuuuu
008	230228s2014 xx \|\|\|\|\|o 00\| \|\|rus c
035			\|a (DE-627)DOAJ065623843
035			\|a (DE-599)DOAJf7ff29e13c9346798e1f1779d7bbc42b
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a rus
100	0		\|a E. A. Moskalenko \|e verfasserin \|4 aut
245	1	0	\|a CURRENT APPROACHES TO DIAGNOSING PROSTATE CANCER, BY APPLYING MAGNETIC RESONANCE SPECTROSCOPY (A CLINICAL STUDY)
264		1	\|c 2014
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a <p<By evaluating abnormal metabolism, magnetic resonance spectroscopy (MRS) is a highly effective tool for diagnosing prostate cancer (PC). Our study has indicated that the level of citrate (Ci) and the ratio of the content of choline (Cho) and creatine (Cr) to that of citrate ((Cho + Cr)/Ci) are the most sensitive and specific indicators. These may be effectively used separately (to diagnose tumor involvement and to determine the degree of tumor differentiation) and as a part of the authors’ discriminant model.</p<<p<The findings suggest that it is expedient to use MRS in the comprehensive diagnosis of PC.</p<
650		4	\|a prostate cancer
650		4	\|a magnetic resonance spectroscopy
650		4	\|a citrate
650		4	\|a choline
650		4	\|a creatine
653		0	\|a Medicine
653		0	\|a R
700	0		\|a S. B. Petrov \|e verfasserin \|4 aut
700	0		\|a Yu. V. Tolkach \|e verfasserin \|4 aut
700	0		\|a A. V. Mishchenko \|e verfasserin \|4 aut
773	0	8	\|i In \|t Onkourologiâ \|d ABV-press, 2015 \|g 7(2014), 1, Seite 25-30 \|w (DE-627)1736705067 \|x 17269776 \|7 nnns
773	1	8	\|g volume:7 \|g year:2014 \|g number:1 \|g pages:25-30
856	4	0	\|u https://doaj.org/article/f7ff29e13c9346798e1f1779d7bbc42b \|z kostenfrei
856	4	0	\|u http://oncourology.abvpress.ru/index.php/oncur/article/view/47 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1726-9776 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1996-1812 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 7 \|j 2014 \|e 1 \|h 25-30

Indexfelder

author_variant	e a m eam s b p sbp y v t yvt a v m avm
matchkey_str	article:17269776:2014----::urnapocetdansnpottcnebapynmgeirsnnep
hierarchy_sort_str	2014
publishDate	2014
allfields	(DE-627)DOAJ065623843 (DE-599)DOAJf7ff29e13c9346798e1f1779d7bbc42b DE-627 ger DE-627 rakwb rus E. A. Moskalenko verfasserin aut CURRENT APPROACHES TO DIAGNOSING PROSTATE CANCER, BY APPLYING MAGNETIC RESONANCE SPECTROSCOPY (A CLINICAL STUDY) 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<By evaluating abnormal metabolism, magnetic resonance spectroscopy (MRS) is a highly effective tool for diagnosing prostate cancer (PC). Our study has indicated that the level of citrate (Ci) and the ratio of the content of choline (Cho) and creatine (Cr) to that of citrate ((Cho + Cr)/Ci) are the most sensitive and specific indicators. These may be effectively used separately (to diagnose tumor involvement and to determine the degree of tumor differentiation) and as a part of the authors’ discriminant model.</p<<p<The findings suggest that it is expedient to use MRS in the comprehensive diagnosis of PC.</p< prostate cancer magnetic resonance spectroscopy citrate choline creatine Medicine R S. B. Petrov verfasserin aut Yu. V. Tolkach verfasserin aut A. V. Mishchenko verfasserin aut In Onkourologiâ ABV-press, 2015 7(2014), 1, Seite 25-30 (DE-627)1736705067 17269776 nnns volume:7 year:2014 number:1 pages:25-30 https://doaj.org/article/f7ff29e13c9346798e1f1779d7bbc42b kostenfrei http://oncourology.abvpress.ru/index.php/oncur/article/view/47 kostenfrei https://doaj.org/toc/1726-9776 Journal toc kostenfrei https://doaj.org/toc/1996-1812 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2014 1 25-30
spelling	(DE-627)DOAJ065623843 (DE-599)DOAJf7ff29e13c9346798e1f1779d7bbc42b DE-627 ger DE-627 rakwb rus E. A. Moskalenko verfasserin aut CURRENT APPROACHES TO DIAGNOSING PROSTATE CANCER, BY APPLYING MAGNETIC RESONANCE SPECTROSCOPY (A CLINICAL STUDY) 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<By evaluating abnormal metabolism, magnetic resonance spectroscopy (MRS) is a highly effective tool for diagnosing prostate cancer (PC). Our study has indicated that the level of citrate (Ci) and the ratio of the content of choline (Cho) and creatine (Cr) to that of citrate ((Cho + Cr)/Ci) are the most sensitive and specific indicators. These may be effectively used separately (to diagnose tumor involvement and to determine the degree of tumor differentiation) and as a part of the authors’ discriminant model.</p<<p<The findings suggest that it is expedient to use MRS in the comprehensive diagnosis of PC.</p< prostate cancer magnetic resonance spectroscopy citrate choline creatine Medicine R S. B. Petrov verfasserin aut Yu. V. Tolkach verfasserin aut A. V. Mishchenko verfasserin aut In Onkourologiâ ABV-press, 2015 7(2014), 1, Seite 25-30 (DE-627)1736705067 17269776 nnns volume:7 year:2014 number:1 pages:25-30 https://doaj.org/article/f7ff29e13c9346798e1f1779d7bbc42b kostenfrei http://oncourology.abvpress.ru/index.php/oncur/article/view/47 kostenfrei https://doaj.org/toc/1726-9776 Journal toc kostenfrei https://doaj.org/toc/1996-1812 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2014 1 25-30
allfields_unstemmed	(DE-627)DOAJ065623843 (DE-599)DOAJf7ff29e13c9346798e1f1779d7bbc42b DE-627 ger DE-627 rakwb rus E. A. Moskalenko verfasserin aut CURRENT APPROACHES TO DIAGNOSING PROSTATE CANCER, BY APPLYING MAGNETIC RESONANCE SPECTROSCOPY (A CLINICAL STUDY) 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<By evaluating abnormal metabolism, magnetic resonance spectroscopy (MRS) is a highly effective tool for diagnosing prostate cancer (PC). Our study has indicated that the level of citrate (Ci) and the ratio of the content of choline (Cho) and creatine (Cr) to that of citrate ((Cho + Cr)/Ci) are the most sensitive and specific indicators. These may be effectively used separately (to diagnose tumor involvement and to determine the degree of tumor differentiation) and as a part of the authors’ discriminant model.</p<<p<The findings suggest that it is expedient to use MRS in the comprehensive diagnosis of PC.</p< prostate cancer magnetic resonance spectroscopy citrate choline creatine Medicine R S. B. Petrov verfasserin aut Yu. V. Tolkach verfasserin aut A. V. Mishchenko verfasserin aut In Onkourologiâ ABV-press, 2015 7(2014), 1, Seite 25-30 (DE-627)1736705067 17269776 nnns volume:7 year:2014 number:1 pages:25-30 https://doaj.org/article/f7ff29e13c9346798e1f1779d7bbc42b kostenfrei http://oncourology.abvpress.ru/index.php/oncur/article/view/47 kostenfrei https://doaj.org/toc/1726-9776 Journal toc kostenfrei https://doaj.org/toc/1996-1812 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2014 1 25-30
allfieldsGer	(DE-627)DOAJ065623843 (DE-599)DOAJf7ff29e13c9346798e1f1779d7bbc42b DE-627 ger DE-627 rakwb rus E. A. Moskalenko verfasserin aut CURRENT APPROACHES TO DIAGNOSING PROSTATE CANCER, BY APPLYING MAGNETIC RESONANCE SPECTROSCOPY (A CLINICAL STUDY) 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<By evaluating abnormal metabolism, magnetic resonance spectroscopy (MRS) is a highly effective tool for diagnosing prostate cancer (PC). Our study has indicated that the level of citrate (Ci) and the ratio of the content of choline (Cho) and creatine (Cr) to that of citrate ((Cho + Cr)/Ci) are the most sensitive and specific indicators. These may be effectively used separately (to diagnose tumor involvement and to determine the degree of tumor differentiation) and as a part of the authors’ discriminant model.</p<<p<The findings suggest that it is expedient to use MRS in the comprehensive diagnosis of PC.</p< prostate cancer magnetic resonance spectroscopy citrate choline creatine Medicine R S. B. Petrov verfasserin aut Yu. V. Tolkach verfasserin aut A. V. Mishchenko verfasserin aut In Onkourologiâ ABV-press, 2015 7(2014), 1, Seite 25-30 (DE-627)1736705067 17269776 nnns volume:7 year:2014 number:1 pages:25-30 https://doaj.org/article/f7ff29e13c9346798e1f1779d7bbc42b kostenfrei http://oncourology.abvpress.ru/index.php/oncur/article/view/47 kostenfrei https://doaj.org/toc/1726-9776 Journal toc kostenfrei https://doaj.org/toc/1996-1812 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2014 1 25-30
allfieldsSound	(DE-627)DOAJ065623843 (DE-599)DOAJf7ff29e13c9346798e1f1779d7bbc42b DE-627 ger DE-627 rakwb rus E. A. Moskalenko verfasserin aut CURRENT APPROACHES TO DIAGNOSING PROSTATE CANCER, BY APPLYING MAGNETIC RESONANCE SPECTROSCOPY (A CLINICAL STUDY) 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<By evaluating abnormal metabolism, magnetic resonance spectroscopy (MRS) is a highly effective tool for diagnosing prostate cancer (PC). Our study has indicated that the level of citrate (Ci) and the ratio of the content of choline (Cho) and creatine (Cr) to that of citrate ((Cho + Cr)/Ci) are the most sensitive and specific indicators. These may be effectively used separately (to diagnose tumor involvement and to determine the degree of tumor differentiation) and as a part of the authors’ discriminant model.</p<<p<The findings suggest that it is expedient to use MRS in the comprehensive diagnosis of PC.</p< prostate cancer magnetic resonance spectroscopy citrate choline creatine Medicine R S. B. Petrov verfasserin aut Yu. V. Tolkach verfasserin aut A. V. Mishchenko verfasserin aut In Onkourologiâ ABV-press, 2015 7(2014), 1, Seite 25-30 (DE-627)1736705067 17269776 nnns volume:7 year:2014 number:1 pages:25-30 https://doaj.org/article/f7ff29e13c9346798e1f1779d7bbc42b kostenfrei http://oncourology.abvpress.ru/index.php/oncur/article/view/47 kostenfrei https://doaj.org/toc/1726-9776 Journal toc kostenfrei https://doaj.org/toc/1996-1812 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2014 1 25-30
language	Russian
source	In Onkourologiâ 7(2014), 1, Seite 25-30 volume:7 year:2014 number:1 pages:25-30
sourceStr	In Onkourologiâ 7(2014), 1, Seite 25-30 volume:7 year:2014 number:1 pages:25-30
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	prostate cancer magnetic resonance spectroscopy citrate choline creatine Medicine R
isfreeaccess_bool	true
container_title	Onkourologiâ
authorswithroles_txt_mv	E. A. Moskalenko @@aut@@ S. B. Petrov @@aut@@ Yu. V. Tolkach @@aut@@ A. V. Mishchenko @@aut@@
publishDateDaySort_date	2014-01-01T00:00:00Z
hierarchy_top_id	1736705067
id	DOAJ065623843
language_de	russisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ065623843</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230228043827.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2014 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ065623843</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf7ff29e13c9346798e1f1779d7bbc42b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">E. A. Moskalenko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">CURRENT APPROACHES TO DIAGNOSING PROSTATE CANCER, BY APPLYING MAGNETIC RESONANCE SPECTROSCOPY (A CLINICAL STUDY)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<By evaluating abnormal metabolism, magnetic resonance spectroscopy (MRS) is a highly effective tool for diagnosing prostate cancer (PC). Our study has indicated that the level of citrate (Ci) and the ratio of the content of choline (Cho) and creatine (Cr) to that of citrate ((Cho + Cr)/Ci) are the most sensitive and specific indicators. These may be effectively used separately (to diagnose tumor involvement and to determine the degree of tumor differentiation) and as a part of the authors’ discriminant model.</p<<p<The findings suggest that it is expedient to use MRS in the comprehensive diagnosis of PC.</p<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prostate cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">magnetic resonance spectroscopy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">citrate</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">choline</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">creatine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. B. Petrov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yu. V. Tolkach</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. V. Mishchenko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Onkourologiâ</subfield><subfield code="d">ABV-press, 2015</subfield><subfield code="g">7(2014), 1, Seite 25-30</subfield><subfield code="w">(DE-627)1736705067</subfield><subfield code="x">17269776</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:25-30</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f7ff29e13c9346798e1f1779d7bbc42b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://oncourology.abvpress.ru/index.php/oncur/article/view/47</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1726-9776</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1996-1812</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2014</subfield><subfield code="e">1</subfield><subfield code="h">25-30</subfield></datafield></record></collection>
author	E. A. Moskalenko
spellingShingle	E. A. Moskalenko misc prostate cancer misc magnetic resonance spectroscopy misc citrate misc choline misc creatine misc Medicine misc R CURRENT APPROACHES TO DIAGNOSING PROSTATE CANCER, BY APPLYING MAGNETIC RESONANCE SPECTROSCOPY (A CLINICAL STUDY)
authorStr	E. A. Moskalenko
ppnlink_with_tag_str_mv	@@773@@(DE-627)1736705067
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut
collection	DOAJ
remote_str	true
illustrated	Not Illustrated
issn	17269776
topic_title	CURRENT APPROACHES TO DIAGNOSING PROSTATE CANCER, BY APPLYING MAGNETIC RESONANCE SPECTROSCOPY (A CLINICAL STUDY) prostate cancer magnetic resonance spectroscopy citrate choline creatine
topic	misc prostate cancer misc magnetic resonance spectroscopy misc citrate misc choline misc creatine misc Medicine misc R
topic_unstemmed	misc prostate cancer misc magnetic resonance spectroscopy misc citrate misc choline misc creatine misc Medicine misc R
topic_browse	misc prostate cancer misc magnetic resonance spectroscopy misc citrate misc choline misc creatine misc Medicine misc R
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Onkourologiâ
hierarchy_parent_id	1736705067
hierarchy_top_title	Onkourologiâ
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1736705067
title	CURRENT APPROACHES TO DIAGNOSING PROSTATE CANCER, BY APPLYING MAGNETIC RESONANCE SPECTROSCOPY (A CLINICAL STUDY)
ctrlnum	(DE-627)DOAJ065623843 (DE-599)DOAJf7ff29e13c9346798e1f1779d7bbc42b
title_full	CURRENT APPROACHES TO DIAGNOSING PROSTATE CANCER, BY APPLYING MAGNETIC RESONANCE SPECTROSCOPY (A CLINICAL STUDY)
author_sort	E. A. Moskalenko
journal	Onkourologiâ
journalStr	Onkourologiâ
lang_code	rus
isOA_bool	true
recordtype	marc
publishDateSort	2014
contenttype_str_mv	txt
container_start_page	25
author_browse	E. A. Moskalenko S. B. Petrov Yu. V. Tolkach A. V. Mishchenko
container_volume	7
format_se	Elektronische Aufsätze
author-letter	E. A. Moskalenko
author2-role	verfasserin
title_sort	current approaches to diagnosing prostate cancer, by applying magnetic resonance spectroscopy (a clinical study)
title_auth	CURRENT APPROACHES TO DIAGNOSING PROSTATE CANCER, BY APPLYING MAGNETIC RESONANCE SPECTROSCOPY (A CLINICAL STUDY)
abstract	<p<By evaluating abnormal metabolism, magnetic resonance spectroscopy (MRS) is a highly effective tool for diagnosing prostate cancer (PC). Our study has indicated that the level of citrate (Ci) and the ratio of the content of choline (Cho) and creatine (Cr) to that of citrate ((Cho + Cr)/Ci) are the most sensitive and specific indicators. These may be effectively used separately (to diagnose tumor involvement and to determine the degree of tumor differentiation) and as a part of the authors’ discriminant model.</p<<p<The findings suggest that it is expedient to use MRS in the comprehensive diagnosis of PC.</p<
abstractGer	<p<By evaluating abnormal metabolism, magnetic resonance spectroscopy (MRS) is a highly effective tool for diagnosing prostate cancer (PC). Our study has indicated that the level of citrate (Ci) and the ratio of the content of choline (Cho) and creatine (Cr) to that of citrate ((Cho + Cr)/Ci) are the most sensitive and specific indicators. These may be effectively used separately (to diagnose tumor involvement and to determine the degree of tumor differentiation) and as a part of the authors’ discriminant model.</p<<p<The findings suggest that it is expedient to use MRS in the comprehensive diagnosis of PC.</p<
abstract_unstemmed	<p<By evaluating abnormal metabolism, magnetic resonance spectroscopy (MRS) is a highly effective tool for diagnosing prostate cancer (PC). Our study has indicated that the level of citrate (Ci) and the ratio of the content of choline (Cho) and creatine (Cr) to that of citrate ((Cho + Cr)/Ci) are the most sensitive and specific indicators. These may be effectively used separately (to diagnose tumor involvement and to determine the degree of tumor differentiation) and as a part of the authors’ discriminant model.</p<<p<The findings suggest that it is expedient to use MRS in the comprehensive diagnosis of PC.</p<
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	CURRENT APPROACHES TO DIAGNOSING PROSTATE CANCER, BY APPLYING MAGNETIC RESONANCE SPECTROSCOPY (A CLINICAL STUDY)
url	https://doaj.org/article/f7ff29e13c9346798e1f1779d7bbc42b http://oncourology.abvpress.ru/index.php/oncur/article/view/47 https://doaj.org/toc/1726-9776 https://doaj.org/toc/1996-1812
remote_bool	true
author2	S. B. Petrov Yu. V. Tolkach A. V. Mishchenko
author2Str	S. B. Petrov Yu. V. Tolkach A. V. Mishchenko
ppnlink	1736705067
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
up_date	2024-07-03T15:44:22.709Z
_version_	1803573225284698112
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ065623843</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230228043827.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2014 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ065623843</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf7ff29e13c9346798e1f1779d7bbc42b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">E. A. Moskalenko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">CURRENT APPROACHES TO DIAGNOSING PROSTATE CANCER, BY APPLYING MAGNETIC RESONANCE SPECTROSCOPY (A CLINICAL STUDY)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<By evaluating abnormal metabolism, magnetic resonance spectroscopy (MRS) is a highly effective tool for diagnosing prostate cancer (PC). Our study has indicated that the level of citrate (Ci) and the ratio of the content of choline (Cho) and creatine (Cr) to that of citrate ((Cho + Cr)/Ci) are the most sensitive and specific indicators. These may be effectively used separately (to diagnose tumor involvement and to determine the degree of tumor differentiation) and as a part of the authors’ discriminant model.</p<<p<The findings suggest that it is expedient to use MRS in the comprehensive diagnosis of PC.</p<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prostate cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">magnetic resonance spectroscopy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">citrate</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">choline</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">creatine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. B. Petrov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yu. V. Tolkach</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. V. Mishchenko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Onkourologiâ</subfield><subfield code="d">ABV-press, 2015</subfield><subfield code="g">7(2014), 1, Seite 25-30</subfield><subfield code="w">(DE-627)1736705067</subfield><subfield code="x">17269776</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:25-30</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f7ff29e13c9346798e1f1779d7bbc42b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://oncourology.abvpress.ru/index.php/oncur/article/view/47</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1726-9776</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1996-1812</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2014</subfield><subfield code="e">1</subfield><subfield code="h">25-30</subfield></datafield></record></collection>
score	7.402135

Nicht das Richtige dabei?

Schreiben Sie uns!

CURRENT APPROACHES TO DIAGNOSING PROSTATE CANCER, BY APPLYING MAGNETIC RESONANCE SPECTROSCOPY (A CLINICAL STUDY)

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?